Abstracts

144-WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT-NAIVE ADULTS ≥50 YRS

As people living with HIV age, identifying effective and safe regimens for older individuals is of heightened importance. The single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) may benefit older adults due to its favorable adverse event (AE) profile and few drug interactions. We conducted two randomized, double blind, phase 3 studies of B/F/TAF in treatment-naïve…

CLINICAL AND LABORATORY OUTCOMES 24 WEEKS AFTER STARTING DTG VERSUS EFV IN ACUTE HIV

This study compared clinical and laboratory parameters before and after initiating Efavirenz(EFV)- and Dolutegravir(DTG)-based antiretroviral therapy (ART), the prior and current 1st line ART, during acute HIV infection (AHI). Individuals with AHI (Fiebig I-V) enrolled in the RV254 cohort in Thailand initiated ART within days (median=0; IQR 0-1) after diagnosis (EFV+2 NRTI: 2009-Jan2017; DTG+2 NRTI:…

A LONG-ACTING NANOFORMULATED TENOFOVIR PRODRUG

Despite the success of existing antiretroviral therapy (ART) in controlling human immunodeficiency virus type 1 (HIV-1) infection, treatment requires life-long adherence to medicines. ART compliance can be compromised by frequency of dosing, and long acting formulations could potentially improve patient adherence. However, the hydrophilic nature of nucleoside reverse transcriptase inhibitors (NRTI) limits their transformation into long…